Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LISA-1: Letrozole ISM PK/Safety Study
NCT03401320Phase 1Completed
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Nov 2017
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of letrozole in breast cancer (4 cohorts), sponsored by Laboratorios Farmacéuticos ROVI. Primary endpoints: Terminal elimination rate constant (lambda_z), Maximum Plasma Concentration (Cmax) and 10 more. Started Nov 2017; status: completed.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03401320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401320.